Strengths and limitations
Comparisons of prescribing quality between settings based on published studies are difficult, due to different approaches to implementation of Beers or similar criteria.21 The present study overcomes this problem by making comparisons using the same approach to criteria implementation in each setting.
The Beers criteria were developed in the US, and some have questioned the appropriateness of their application in Europe, on account of differences in practice and drug availability.22 The present results do not support this concern, as similar medications make a large contribution to inappropriate prescribing in both countries. Other newer measures of prescribing quality are available but the Beers criteria have the advantage of simplicity, especially where recording of comorbidity may vary between settings. The analysis of ‘concern’ drug groups in this study allows an alternate description of prescribing quality, by capturing prescribing across a range of medications that put older people at risk of serious adverse events through excessive use.
The analysis did not adjust comparisons between settings for comorbidities or polypharmacy. The rationale for this is that many drugs, such as anticholinergic and psychotropic medication, impair functional status and their impact on quality of life will be greater in patients with high levels of frailty or comorbidity. Adjustment for comorbidity may mask poor prescribing to vulnerable older people and give a falsely optimistic estimate of potentially harmful prescribing in care homes. Furthermore, differences in recording of comorbidities between settings would lead to biased estimates after adjustment.
Comparison with existing literature
The findings of this study are consistent with existing studies that describe high use of psychotropic and potentially inappropriate medication in US nursing home settings.5,9,23 In terms of prevalence and characteristics of inappropriate prescribing, the present findings are very similar to a recent Australian study.6 Studies that allow comparison between residential settings are limited. A recent regional Scottish study described a 30% higher unadjusted use of potentially inappropriate medication in care homes compared to the community, and a US study that examined inappropriate prescribing in three residential settings showed higher levels of inappropriate prescribing in nursing homes compared to the general community.9,24 The present authors, and others, have previously described the strong relationship between polypharmacy and receipt of potentially inappropriate medication and the present findings are consistent with this explanation for higher levels of inappropriate prescribing in care homes.17,22,24
Implications for practice and research
The high use of antipsychotic medication in care homes is a well-recognised concern and the focus of a national policy initiative.25 The authors have previously described antipsychotic prescribing in care homes and most prescribing is to patients with dementia without a diagnosis of severe mental illness.26 The higher use of benzodiazepines and anticholinergic medication in care homes is a concern, as these drugs have been specifically identified as leading to functional impairment.2,3 The lower use of NSAIDs in care homes suggests that concerns over adverse events in older people has influenced prescribing but this finding needs to be considered in the context of the overall quality of pain management, which is beyond the scope of this study.
High use of loop diuretics, despite similar heart failure prevalence to the community, suggests either inadequate recording of heart failure or inappropriate use of diuretics for the management of dependent oedema. The authors have previously found that chronic disease may be under-identified in UK care homes and that prescribing of angiotensin-converting enzyme inhibitors for heart failure was lower in care homes than in the community.13,14 Overall, the markedly lower use of cardiovascular medication in care homes compared to the community is noteworthy. The most common indication for prescribing cardiovascular medications is treatment of hypertension, which is less likely to be diagnosed in care home patients.13 Further work is required to determine whether this lower use of cardiovascular medication in care homes is appropriate.
The high use of laxative medicines and nutritional supplements, although not necessarily a risk for older people, suggests a need for improved dietary management and reinforces concerns over nutrition in care homes.27,28 Higher antibiotic use in care homes may be appropriate, given resident frailty, but highlights the risk of antibiotic resistance in communal settings and the need for vigilance.
The strong association between polypharmacy and potentially inappropriate prescribing, prima facie, supports UK policy, which incentivises medication reviews for patients on repeat medication. However, as the vast majority of patients in care homes receive multiple medications, such an approach will lack specificity in care homes. Furthermore, evidence suggests that total drug use is less important than the contribution of specific drugs to functional impairment in older people, and the authors have previously shown that increased prescribing, as a result of the Quality and Outcomes Framework, has not necessarily increased potentially inappropriate prescribing.2,16 This suggests an approach targeted at risk, rather than repeat, prescribing may be more effective in improving wellbeing for older people.
The comparison with the US, although subject to caveats inherent in such international comparisons, suggests that the quality of prescribing in UK nursing homes is similar, at least based on the measures in the Beers criteria. This is surprising, as US nursing homes are subject to legislative regulation that includes monitoring of many drugs included in the Beers criteria.8 The comparison, in this study, between community and care home settings in the UK suggests that higher uptake of incentivised reviews in care homes does not prevent higher levels of inappropriate prescribing. This emphasises the need for additional effective interventions to improve prescribing quality, in addition to either regulation or incentivised medication reviews. This conclusion is consistent with evidence that questions the effectiveness of medication reviews in care homes and mandatory drug reviews in the US.29–31
In conclusion, there is potential for improving the quality of prescribing in care homes. In particular, reducing the high use of anticholinergic and psychotropic medication could improve function and wellbeing in a vulnerable population. Improving prescribing in care homes presents a challenge to physicians, who need to balance the increasing demands for effective prescribing with the need to minimise adverse events. There is a need for evidence-based prescribing interventions in care homes, which are more effective and focused than current incentivised medication reviews.29,32